参考文献/References:
[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74-108.
[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[3] 方京龙, 刘淑玲, 张广明. 肝硬化和肝癌MRI诊断研究进展[J]. 国际放射医学核医学杂志, 2014, 38(3):207-211.
[4] Murakami T, Kim T, Takamura M, et al. Hypervascular hepatocell-ular carcinoma:detection with double arterial phase multi-detec-tor row helical CT[J]. Radiology, 2001, 218(3):763-767.
[5] Liu S, Wah Chan K, Tong J, et al. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcino-ma:a case report and a summary of recent literature[J]. QJM, 2011, 104(6):477-483.
[6] Sharma B, Martin A, Zerizer I. Positron emission tomography-com-puted tomography in liver imaging[J]. Semin Ultrasound CT MR, 2013, 34(1):66-80.
[7] Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors[J]. J Cancer Res Clin Oncol, 2004, 130(5):266-272.
[8] Chen YK, Hsieh DS, Liao CS, et al. Utility of FDG-PET for investi-gating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence[J]. Anticancer Res, 2005, 25(6C):4719-4725.
[9] Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metasta-tic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12):1912-1921.
[10] Wolfort RM, Papillion PW, Turnage RH, et al. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with com-parison of tumor size, AFP level and histologic grade[J]. Int Surg, 2010, 95(1):67-75.
[11] Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using[18F] fluorocholine:preliminary comparison with[18F] FDG PET/CT[J]. Eur J Nucl Med Mol Ima-ging, 2006, 33(11):1285-1289.
[12] Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-gly-coprotein expression, and outcome after resection in hepatocellular carcinoma[J]. Clin cancer Res, 2007, 13(2 Pt 1):427-433.
[13] Seo S, Hatano E, Higashi T, et al. P-glycoprotein expression affects[18F] fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro[J]. Int J Oncol, 2009, 34(5):1303-1312.
[14] 吴冰, 韩磊, 姜磊, 等. 18F-FDG PET/CT双时相显像在肝细胞肝癌诊断中的应用价值[J]. 中华核医学与分子影像杂志, 2014, 34(1):58-59.
[15] Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of ac-etate metabolism in tumor cells in relation to cell proliferation:acetate metabolism in tumor cells[J]. Nucl Med Biol, 2001, 28(2):117-122.
[16] Salem N, Kuang Y, Corn D, et al.[(Methyl)1-11C]-acetate metabolism in hepatocellular carcinoma[J]. Mol Imaging Biol, 2011, 13(1):140-151.
[17] Yun M, Bang SH, Kim JW, et al. The importance of acetyl coen-zyme A synthetase for 11C-acetate uptake and cell survival in hepa-tocellular carcinoma[J]. J Nucl Med, 2009, 50(8):1222-1228.
[18] Kuang Y, Salem N, Wang F, et al. A colorimetric assay method to measure acetyl-CoA synthetase activity:application to woodchuck model of hepatitis virus-induced hepatocellular carcinoma[J]. J Biochem Biophys Methods, 2007, 70(4):649-655.
[19] Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocell-ular carcinoma and other liver masses[J]. J Nucl Med, 2003, 44(2):213-221.
[20] Hwang KH, Choi DJ, Lee SY, et al. Evaluation of patients with hepa-tocellular carcinomas using[11C]acetate and[18F] FDG PET/CT:A preliminary study[J]. Appl Radiat Isot, 2009, 67(7-8):1195-1198.
[21] Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate:a poten-tial acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11C-acetate[J]. J Nucl Med, 2007, 48(3):420-428.
[22] Takemoto K, Hatano E, Nishii R, et al. Assessment of[18F]-fluo-roacetate PET/CT as a tumor-imaging modality:preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor[J]. Ann Nucl Med, 2014, 28(4):371-380.
[23] Lindhe O, Sun A, Ulin J, et al.[18F] Fluoroacetate is not a functional analogue of[11C] acetate in normal physiology[J]. Eur J Nucl Med Mol Imaging, 2009, 36(9):1453-1459.
[24] Ho CL, Cheung MK, Chen S, et al. 18F-fluoroacetate positron emi-ssion tomography for hepatocellular carcinoma and metastases:an alternative tracer for 11C-acetate?[J]. Mol Imaging, 2012, 11(3):229-239.
[25] Tenley N, Corn DJ, Yuan L, et al. The effect of fasting on PET Imaging of Hepatocellular Carcinoma[J]. J Cancer Ther, 2013, 4(2):561-567.
[26] Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors:comparison of 11C-choline PET with 18F-FDG PET[J]. J Nucl Med, 2003, 44(7):1051-1056.
[27] Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F] fluoro-D-glucose, 6-deoxy-6[18F] flu-oro-D-glucose,[1-11C]-acetate and[N-methyl-11C]-choline[J]. Q J Nucl Med Mol Imaging, 2009, 53(2):144-156.
[28] Kuang Y, Salem N, Tian H, et al. Imaging lipid synthesis in hepato-cellular carcinoma with[methyl-11c]choline:correlation with in vivo metabolic studies[J]. J Nucl Med, 2011, 52(1):98-106.
[29] Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepa-tocellular carcinoma using 11C-choline PET:comparison with 18F-FDG PET[J]. J Nucl Med, 2008, 49(8):1245-1248.
[30] Balogova S, Bumsel F, Kerrou K, et al. La fluorocholine (18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépato-cellulaire… parfois chez le même malade[J]. Médecine Nucléaire, 2010, 34(7):378-382.
[31] Liu Q, Peng ZM, Liu QW, et a1. The role of 11C-choline positron emission tomography-computed tomography and videomedi-astinoscopy in the evaluation of diseases of middle mediastinum[J]. Chin Med J(Engl), 2006, 119(8):634-639.
[32] Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer[J]. Eur Urol, 2011, 59(1):51-60.
[33] Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of 18FLT and 18FDG uptake on PET with Ki-67 immunohistochemistry in non small lung cancer[J]. Eur J Nucl Med Mol Imaging, 2007, 34(10):1610-1616.
[34] Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymi-dine[J]. J Nucl Med, 2009, 50(9):1441-1447.
相似文献/References:
[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]张毓艺,姚稚明.18F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(6):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
Zhang Yuyi,Yao Zhiming.The progress of 18F-FDG PET/CT in the diagnosis of N-staging of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):447.[doi:10.3760/cma.j.issn.1673-4114.2016.06.009]
[3]李欢欢,李素平,游金辉.小细胞肺癌伴副肿瘤综合征患者骨显像示肌肉摄取一例[J].国际放射医学核医学杂志,2014,38(2):140.[doi:10.3760/cma.j.issn.1673-4114.2014.02.016]
[4]戈畅,梁硕.化疗联合DC-CIK生物治疗非小细胞肺癌的临床价值及CT灌注成像的疗效评价[J].国际放射医学核医学杂志,2014,38(6):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
Ge Chang,Liang Shuo.The clinical value and CT perfusion evaluation in chemotherapy combined with DC-CIK biological treatment of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):377.[doi:10.3760/cma.j.issn.1673-4114.2014.06.007]
[5]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[6]龙再颖,汤春静,于立明,等.甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究[J].国际放射医学核医学杂志,2013,37(1):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
LONG Zai-ying,TANG Chun-jing,YU Li-ming,et al.The correlation between the stimulated thyroglobulin level after surgery in papillary thyroid carcinoma and cervical lymph node metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):27.[doi:10.3760/cma.j.issn.1673-4114.2013.01.008]
[7]于丽娟,李迎辞,王文志,等.PET-CT及PET-CT结合Lung VCAR软件对非小细胞肺癌肺门区淋巴结的诊断分析[J].国际放射医学核医学杂志,2012,36(6):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
YU Li-juan,LI Ying-ci,WANG Wen-zhi,et al.Value of PET-CT and PET-CT combined with Lung VCAR software in the diagnosis of hilar area lymph nodes of non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):323.[doi:10.3760/cma.j.issn.1673-4114.2012.06.002]
[8]刘莉,杨景魁.125I粒子植入治疗非小细胞肺癌的护理及辐射防护[J].国际放射医学核医学杂志,2012,36(3):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
LIU Li,YANG Jing-kui.Radiation protective nursing intervene of 125I seed implantation in non-small cell lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):172.[doi:10.3760/cma.j.issn.1673-4114.2012.03.013]
[9]朱晓琳,李强.肝腺瘤的影像诊断现状及进展[J].国际放射医学核医学杂志,2011,35(2):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
ZHU Xiao-lin,LI Qiang.Status and advances in imaging diagnsis of hepatic adenoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):124.[doi:10.3760/cma.j.issn.1673-4114.2011.02.014]
[10]梁吉祥,柴树德,郑广钧,等.CT引导下植入125I粒子治疗非小细胞肺癌切除术后局部复发的疗效[J].国际放射医学核医学杂志,2011,35(3):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
LIANG Ji-xiang,CHAI Shu-de,ZHENG Guang-jun,et al.CT-guided percutaneous interstitial implantation of 125I for recurrent patients of postoperative non-small cell lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):181.[doi:10.3760/cma.j.issn.1673-4114.2011.03.012]
[11]万绪明,许祖闪,侯红军.磁共振表观弥散系数变化率对肝细胞肝癌患者单次TACE术后疗效评价的应用价值[J].国际放射医学核医学杂志,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
Wan Xuming,Xu Zushan,Hou Hongjun.Applieation value of the change ratio of apparent diffusion coefficient in the therapeutic evaluation of hepatocellular carcinoma treated by single transcatheter arterial chemoembolization[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):129.[doi:10.3760/cma.j.issn.1673-4114.2015.02.006]
[12]张一秋,石洪成.肝细胞癌肿瘤新生血管影像学评价的研究进展[J].国际放射医学核医学杂志,2013,37(1):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
ZHANG Yi-qiu,SHI Hong-cheng.Advances in assessment of imaging examination for tumor neoangiogenesis induced by hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):60.[doi:10.3760/cma.j.issn.1673-4114.2013.01.015]
[13]李红兵,陈勇,曾建国,等.肝动脉化疗性栓塞结合Ⅱ期手术切除治疗巨块型外生型肝癌[J].国际放射医学核医学杂志,2010,34(1):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
LI Hong-bing,CHEN Yong,ZENG Jian-guo,et al.Treatment of massive extrahepatic growing hepatocellular carcinoma with TACE in combination with secondary resection[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):49.[doi:10.3760/cma.j.issn.1673-4114.2010.01.013]
[14]郑磊,李前伟.18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用[J].国际放射医学核医学杂志,2008,32(1):23.
ZHENG Lei,LI Qian-wei.Application of positron emission tomography with 18F-fluorodeoxyglucose in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):23.
[15]周云,刘璐,宋进华.经肝动脉灌注90Y微球治疗肝癌的研究进展[J].国际放射医学核医学杂志,2006,30(6):321.
ZHOU Yun,LIU Lu,SONG Jin-hua.Clinical researched progress of intra-arterial radioembolization with 90Y-glass microspheres for treatment of hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):321.
[16]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[17]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
[18]陈佩和,徐文贵,李小凤,等.肝细胞肝癌的葡萄糖代谢机制及在PET显像中的应用价值[J].国际放射医学核医学杂志,2018,(6):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]
Chen Peihe,Xu Wengui,Li Xiaofeng,et al.Glycometabolism mechanism in hepatocellular carcinoma and its application in PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):547.[doi:10.3760/cma.j.issn.1673-4114.2018.06.013]